Company profile
Glycemicon
A financing round worth more than CHF 3 million, and clinical trials on both humans and cats: things are progressing nicely at Glycemicon. The startup is working on making a substance that occurs naturally in humans and animals and which is suitable for use in treating diabetes.
Source: startup.ch